Bullish indicating open at $55-$60, IPO prices at $37
LONDON - Proteome Sciences plc, a provider of contract proteomics services, conducted its Annual General Meeting today, where Executive Chairman Christopher Pearce provided an update on the company’s performance and outlook. Pearce noted a continued recovery in the pharmaceutical and biotech markets since the second half of 2024, with an expanding order pipeline now extending into 2026.
The company, which had previously announced a significant service contract with a US pharmaceutical company in February, is witnessing a similar growth trend at its San Diego facility, currently handling eight projects. While recent US tariff changes could potentially impact the revenues from TMT reagent sales, Pearce suggested that any such effect would likely be temporary.
Proteome Sciences is also advancing licensing discussions for its new DXT tags designed for multiplexing data-independent acquisition ( DIA (BME:DIDA)), which are set to be presented at the American Society for Mass Spectrometry in Baltimore this June. Following the completion of its first commercial single-cell proteomics project in January, the company is in talks for a follow-up order and is managing other ongoing SCP projects.
The addition of two mass spectrometry systems at the main Frankfurt site has enabled the company to operate at full capacity, meeting a surge in service orders. Pearce expressed optimism about the company’s proteomics business, which has seen a strong rebound in customer orders and services, positioning it for potential future revenue growth and increased returns.
Proteome Sciences specializes in contract proteomics services to support drug discovery, development, and biomarker identification. The company’s proprietary workflows are designed for the analysis of tissues, cells, and body fluids, employing methods such as SysQuant® and TMT®MS2 for target identification and biological activity mechanisms. It also offers mass spectrometry-based targeted assay development for biomarker analysis.
This report is based on a press release statement issued by Proteome Sciences plc on the occasion of their Annual General Meeting.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.